ES2744828T3 - Gestión de la osteoporosis con PEG APM - Google Patents

Gestión de la osteoporosis con PEG APM Download PDF

Info

Publication number
ES2744828T3
ES2744828T3 ES14764671T ES14764671T ES2744828T3 ES 2744828 T3 ES2744828 T3 ES 2744828T3 ES 14764671 T ES14764671 T ES 14764671T ES 14764671 T ES14764671 T ES 14764671T ES 2744828 T3 ES2744828 T3 ES 2744828T3
Authority
ES
Spain
Prior art keywords
peg
bone
apm
ovx
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14764671T
Other languages
English (en)
Spanish (es)
Inventor
Rifat Pamukcu
Laura Mccabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University
Midway Pharmaceuticals Inc
Original Assignee
Michigan State University
Midway Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University, Midway Pharmaceuticals Inc filed Critical Michigan State University
Application granted granted Critical
Publication of ES2744828T3 publication Critical patent/ES2744828T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14764671T 2013-03-15 2014-03-14 Gestión de la osteoporosis con PEG APM Active ES2744828T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798481P 2013-03-15 2013-03-15
PCT/US2014/028832 WO2014144425A1 (en) 2013-03-15 2014-03-14 Managing osteoporosis with hmw peg

Publications (1)

Publication Number Publication Date
ES2744828T3 true ES2744828T3 (es) 2020-02-26

Family

ID=51537706

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14764671T Active ES2744828T3 (es) 2013-03-15 2014-03-14 Gestión de la osteoporosis con PEG APM

Country Status (11)

Country Link
US (2) US10045949B2 (enExample)
EP (1) EP2968159B1 (enExample)
JP (3) JP6275239B2 (enExample)
AU (2) AU2014229082C1 (enExample)
CY (1) CY1122568T1 (enExample)
DK (1) DK2968159T3 (enExample)
ES (1) ES2744828T3 (enExample)
HU (1) HUE045032T2 (enExample)
PL (1) PL2968159T3 (enExample)
PT (1) PT2968159T (enExample)
WO (1) WO2014144425A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419823B (zh) * 2020-04-30 2022-03-29 上海公谊药业有限公司 一种延胡索酸泰妙菌素肠溶微丸及其制备方法和用途
NL1044084B1 (nl) 2021-07-05 2023-01-11 Evers Agro B V Mestinjecteur

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10338646A (ja) * 1996-08-26 1998-12-22 Takeda Chem Ind Ltd 骨形成促進医薬組成物
ATE544354T1 (de) * 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
JPWO2004105825A1 (ja) * 2003-01-10 2006-07-20 多木化学株式会社 骨形成用生体材料、該材料を含む注入用製剤、及び該材料を調製するためのキット、並びにこれらを用いる骨形成方法
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
US8153112B2 (en) 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
MX2011009988A (es) * 2009-03-23 2011-11-18 Univ Chicago Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D

Also Published As

Publication number Publication date
EP2968159A1 (en) 2016-01-20
EP2968159B1 (en) 2019-06-12
CY1122568T1 (el) 2021-01-27
JP2016513738A (ja) 2016-05-16
JP6275239B2 (ja) 2018-02-07
US20160000730A1 (en) 2016-01-07
AU2014229082A1 (en) 2015-11-05
AU2018250501A1 (en) 2018-11-15
HUE045032T2 (hu) 2019-12-30
JP2017082009A (ja) 2017-05-18
JP6619849B2 (ja) 2019-12-11
AU2014229082C1 (en) 2019-01-17
JP2018162328A (ja) 2018-10-18
DK2968159T3 (da) 2019-08-12
US10045949B2 (en) 2018-08-14
AU2018250501B2 (en) 2020-06-25
PT2968159T (pt) 2019-10-01
AU2014229082B2 (en) 2018-07-19
US20190015353A1 (en) 2019-01-17
PL2968159T3 (pl) 2019-11-29
WO2014144425A1 (en) 2014-09-18
EP2968159A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
ES2936842T3 (es) Composiciones probióticas y prebióticas
ES2379810T3 (es) Composiciones nutracéuticas para el tratamiento de la atrofia muscular
ES2431085T3 (es) Uso de glutamato, derivados o metabolitos de glutamato, análogos de glutamato o mezclas de los mismos para la fabricación de una composición para el tratamiento de osteoporosis
Lyons et al. Strongyloides westeri and Parascaris equorum: Observations in field studies in Thoroughbred foals on some farms in Central Kentucky, USA
Gerber et al. Anabolic steroids reduce muscle damage caused by rotator cuff tendon release in an experimental study in rabbits
Tomaszewska et al. Chronic dietary supplementation with kynurenic acid, a neuroactive metabolite of tryptophan, decreased body weight without negative influence on densitometry and mandibular bone biomechanical endurance in young rats
Draper et al. Comparison of effects of capromorelin and mirtazapine on appetite in New Zealand white rabbits (Oryctolagus cuniculus)
AU2018250501B2 (en) Managing Osteoporosis With HMW PEG
Harvey et al. Effect of daily lithium chloride administration on bone mass and strength in growing broiler chickens
JP2010260864A (ja) 血液殺寄生虫薬
Dumas et al. Effect of creep and post-weaning feeding composition on piglets’ intestinal health and post-weaning growth according to their creep feed consumption status
Bieńko et al. The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment
JP6467513B2 (ja) 体重増加用化合物の長期使用のための組成物と方法
Loh et al. The effects of iron supplementation in preweaning piglets
Somagond et al. Effect of physical form of the therapeutic diet on the behaviour of crossbred calves experimentally infected with foot-and-mouth disease virus
Yan The effects of dietary probiotic inclusion on skeletal health of poultry and its possible mechanisms
Millis et al. Osteoarthritis has a high prevalence in dogs undergoing routine dental prophylaxis
Tymczyna et al. Interrelationships between morphometric, densitometric, and mechanical properties of mandible in 6-month-old male pigs
Spratling et al. Osteodystrophy associated with apparent hypovitaminosis-D in yearling cattle
JP6161494B2 (ja) 血漿タンパクを含有する筋萎縮改善用経口組成物及び筋萎縮改善剤
RU2404728C1 (ru) Способ повышения общей резистентности организма, профилактики и лечения респираторных, желудочно-кишечных и гинекологических заболеваний, профилактики эмбриональной смертности у животных и лекарственное средство для его осуществления
Azizi et al. Sheep abomasal phytobezoariasis: the effect of breed, season and age with histopathological observations
Yumol Determining If Lowering the Level of Dietary Calcium and Vitamin D in AIN-93G Diet Supports Normal Bone Development and Intestinal Integrity in Female CD-1 Mice
Wakefield Effect of altering dietary calcium and vitamin D in AIN93G diet on bone development in CD-1 male mice
JP2015061850A (ja) 抗生物質使用を減らすためのアザペロンの使用